TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07300150: A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Sponsor: PAQ Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 210 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07300150 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07300150 Rescue Dossier →